Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
138.4 EUR | -2.33% | +0.84% | +0.10% |
05-23 | Some of the biggest splits in Corporate America | RE |
05-22 | Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies | RE |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 4 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.10% | 369B | - | ||
+38.69% | 723B | C+ | ||
+34.28% | 595B | B | ||
+20.24% | 332B | B- | ||
+2.12% | 282B | C+ | ||
+17.02% | 244B | B+ | ||
+9.31% | 208B | B- | ||
-5.07% | 205B | A+ | ||
-0.35% | 168B | C+ | ||
+6.42% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson